{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:20:57Z","timestamp":1781871657988,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.bbrc.2022.01.110","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T18:20:02Z","timestamp":1643480402000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["ADAMTS8 inhibited lung cancer progression through suppressing VEGFA"],"prefix":"10.1016","volume":"598","author":[{"given":"Yutian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3302-1970","authenticated-orcid":false,"given":"Fei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2022.01.110_bib1","doi-asserted-by":"crossref","first-page":"s41","DOI":"10.7861\/clinmedicine.18-2-s41","article-title":"Recent advances in the management of lung cancer","volume":"18","author":"Jones","year":"2018","journal-title":"Clin. Med."},{"key":"10.1016\/j.bbrc.2022.01.110_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.path.2019.11.002","article-title":"Targeted therapy and checkpoint immunotherapy in lung cancer","volume":"13","author":"Ruiz-Cordero","year":"2020","journal-title":"Surgical pathology clinics"},{"key":"10.1016\/j.bbrc.2022.01.110_bib3","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/14737140.2020.1787156","article-title":"Molecular therapeutic targets in non-small cell lung cancer","volume":"20","author":"Sankar","year":"2020","journal-title":"Expet Rev. Anticancer Ther."},{"key":"10.1016\/j.bbrc.2022.01.110_bib4","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.bcp.2019.03.033","article-title":"A\u00a0Disintegrin and Metalloproteinase (ADAM) and ADAM with thrombospondin motifs (ADAMTS) family in vascular biology and disease","volume":"164","author":"Zhong","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbrc.2022.01.110_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/biom10050682","article-title":"ADAMTS-15 has a tumor suppressor role in prostate cancer","volume":"10","author":"Binder","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.bbrc.2022.01.110_bib6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.humpath.2018.08.030","article-title":"Overexpression of ADAMTS-2 in tumor cells and stroma is predictive of poor clinical prognosis in gastric cancer","volume":"84","author":"Jiang","year":"2019","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bbrc.2022.01.110_bib7","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1038\/s41467-020-17659-7","article-title":"Identification of relevant genetic alterations in cancer using topological data analysis","volume":"11","author":"Rabad\u00e1n","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2022.01.110_bib8","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.235762","article-title":"ADAMTS-1 and syndecan-4 intersect in the regulation of cell migration and angiogenesis","volume":"133","author":"Lambert","year":"2020","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.bbrc.2022.01.110_bib9","doi-asserted-by":"crossref","first-page":"8078","DOI":"10.1093\/nar\/gkab633","article-title":"Characterization of a functional endothelial super-enhancer that regulates ADAMTS18 and angiogenesis","volume":"49","author":"Mushimiyimana","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbrc.2022.01.110_bib10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.mvr.2017.05.007","article-title":"siRNA-knockdown of ADAMTS-13 modulates endothelial cell angiogenesis","volume":"113","author":"Tang","year":"2017","journal-title":"Microvasc. Res."},{"key":"10.1016\/j.bbrc.2022.01.110_bib11","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/sj.bjc.6602107","article-title":"METH-2 silencing and promoter hypermethylation in NSCLC","volume":"91","author":"Dunn","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2022.01.110_bib12","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The intersection between tumor angiogenesis and immune suppression","volume":"25","author":"Rahma","year":"2019","journal-title":"Clin. Cancer Res. Off. J. Amer. Assoc. Cancer Res."},{"key":"10.1016\/j.bbrc.2022.01.110_bib13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40880-015-0070-2","article-title":"Revisiting tumor angiogenesis: vessel co-option, vessel remodeling, and cancer cell-derived vasculature formation","volume":"35","author":"Qian","year":"2016","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.bbrc.2022.01.110_bib14","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1080\/14728222.2017.1371137","article-title":"VEGF as a potential target in lung cancer","volume":"21","author":"Frezzetti","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bbrc.2022.01.110_bib15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S1470-2045(19)30827-7","article-title":"TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial","volume":"21","author":"Pfeiffer","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2022.01.110_bib16","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s11523-017-0518-1","article-title":"Bevacizumab in colorectal cancer: current role in treatment and the potential of biosimilars","volume":"12","author":"Rosen","year":"2017","journal-title":"Targeted Oncol."},{"key":"10.1016\/j.bbrc.2022.01.110_bib17","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2022.01.110_bib18","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A\u00a0phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2022.01.110_bib19","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2022.01.110_bib20","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2022.01.110_bib21","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.bbrc.2022.01.110_bib22","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.bbrc.2022.01.110_bib23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.bbrc.2022.01.110_bib24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/17476348.2020.1701439","article-title":"Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations","volume":"14","author":"Reck","year":"2020","journal-title":"Expet Rev. Respir. Med."},{"key":"10.1016\/j.bbrc.2022.01.110_bib25","first-page":"27","volume":"vol. 131","author":"Cortot","year":"2020"},{"key":"10.1016\/j.bbrc.2022.01.110_bib26","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.7150\/ijbs.31605","article-title":"Extracellular vesicles (EVs) from lung adenocarcinoma cells promote human umbilical vein endothelial cell (HUVEC) angiogenesis through yes kinase-associated protein (YAP) transport","volume":"15","author":"Wang","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bbrc.2022.01.110_bib27","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1007\/s13277-015-3461-8","article-title":"The roles of ADAMTS in angiogenesis and cancer","volume":"36","author":"Sun","year":"2015","journal-title":"Tumour Biol. J. Int. Soc. Biol. Med."},{"key":"10.1016\/j.bbrc.2022.01.110_bib28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/1742-2094-10-133","article-title":"ADAMTS proteoglycanases in the physiological and pathological central nervous system","volume":"10","author":"Lemarchant","year":"2013","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.bbrc.2022.01.110_bib29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.matbio.2015.02.004","article-title":"ADAMTS proteases in vascular biology","volume":"44\u201346","author":"Rodr\u00edguez-Manzaneque","year":"2015","journal-title":"Matrix Biol. J. Int. Soc. Matrix Biol."},{"key":"10.1016\/j.bbrc.2022.01.110_bib30","doi-asserted-by":"crossref","first-page":"649718","DOI":"10.1155\/2014\/649718","article-title":"ADAMTS-12: a multifaced metalloproteinase in arthritis and inflammation","volume":"2014","author":"Wei","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.bbrc.2022.01.110_bib31","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1080\/01443615.2019.1674265","article-title":"The investigation of serum levels of ADAMTS 5 and 8 (the A disintegrin and metalloproteinase with thrombospondin motifs) in the etiology of endometrial cancer","volume":"40","author":"Yilmaz","year":"2020","journal-title":"J.\u00a0Obstet. Gynaecol"},{"key":"10.1016\/j.bbrc.2022.01.110_bib32","doi-asserted-by":"crossref","first-page":"23349","DOI":"10.1074\/jbc.274.33.23349","article-title":"METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity","volume":"274","author":"V\u00e1zquez","year":"1999","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2022.01.110_bib33","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1038\/sj.onc.1209287","article-title":"Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively","volume":"25","author":"Liu","year":"2006","journal-title":"Oncogene"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X22001486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X22001486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T12:14:32Z","timestamp":1757765672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X22001486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":33,"alternative-id":["S0006291X22001486"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2022.01.110","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ADAMTS8 inhibited lung cancer progression through suppressing VEGFA","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2022.01.110","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}